WO2021162532A3 - Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 - Google Patents

Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 Download PDF

Info

Publication number
WO2021162532A3
WO2021162532A3 PCT/KR2021/001928 KR2021001928W WO2021162532A3 WO 2021162532 A3 WO2021162532 A3 WO 2021162532A3 KR 2021001928 W KR2021001928 W KR 2021001928W WO 2021162532 A3 WO2021162532 A3 WO 2021162532A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
sustained
release microspheres
Prior art date
Application number
PCT/KR2021/001928
Other languages
English (en)
French (fr)
Other versions
WO2021162532A2 (ko
Inventor
나용하
원동필
김예진
이주한
최희경
설은영
이희용
Original Assignee
주식회사 지투지바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 지투지바이오 filed Critical 주식회사 지투지바이오
Priority to AU2021219556A priority Critical patent/AU2021219556A1/en
Priority to JP2022548939A priority patent/JP2023513751A/ja
Priority to EP21754621.7A priority patent/EP4104820A4/en
Priority to BR112022016100A priority patent/BR112022016100A2/pt
Priority to US17/904,133 priority patent/US20230096928A1/en
Priority to MX2022010044A priority patent/MX2022010044A/es
Priority to CA3167978A priority patent/CA3167978A1/en
Priority to CN202180027937.6A priority patent/CN115484935A/zh
Publication of WO2021162532A2 publication Critical patent/WO2021162532A2/ko
Publication of WO2021162532A3 publication Critical patent/WO2021162532A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 세마글루타이드, 이의 약학적으로 허용가능한 염, 수화물 또는 용매화물을 포함하는 서방형 미립구를 포함하여, 약물의 급격한 초기방출(initial burst)을 방지하여 치명적인 부작용을 효과적으로 억제할 수 있고, 입자 크기에 대비하여 높은 함량의 약물을 포함시킬 수 있어 투여시 발생할 수 있는 환자의 고통 및 염증반응을 최소화할 수 있어 당뇨, 베타-세포 기능 보존, 고혈압, 고지혈증, 비만, 비알코올성 지방간염 또는 알츠하이머병 및 파킨슨병 등 퇴행성신경질환의 예방 또는 치료에 유용한 약학적 조성물에 관한 것이다.
PCT/KR2021/001928 2020-02-14 2021-02-15 Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 WO2021162532A2 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2021219556A AU2021219556A1 (en) 2020-02-14 2021-02-15 Pharmaceutical composition comprising sustained-release microspheres including GLP-1 analogue or pharmaceutically acceptable salt thereof
JP2022548939A JP2023513751A (ja) 2020-02-14 2021-02-15 Ｇｌｐ－１アナログ、またはその薬学的に許容可能な塩を含む徐方型微粒球を含む薬学的組成物
EP21754621.7A EP4104820A4 (en) 2020-02-14 2021-02-15 PHARMACEUTICAL COMPOSITION COMPRISING SUSTAINED-RELEASE MICROSPHERES COMPRISING A GLP -1 ANALOG OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
BR112022016100A BR112022016100A2 (pt) 2020-02-14 2021-02-15 Composição farmacêutica compreendendo microgrânulos de liberação sustentada incluindo análogo de glp-1 ou sal farmaceuticamente aceitável do mesmo
US17/904,133 US20230096928A1 (en) 2020-02-14 2021-02-15 Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof
MX2022010044A MX2022010044A (es) 2020-02-14 2021-02-15 Composicion farmaceutica que comprende microesferas de liberacion sostenida que incluyen analogo de glp-1 o sal farmaceuticamente aceptable del mismo.
CA3167978A CA3167978A1 (en) 2020-02-14 2021-02-15 Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof
CN202180027937.6A CN115484935A (zh) 2020-02-14 2021-02-15 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200018640 2020-02-14
KR10-2020-0018640 2020-02-14

Publications (2)

Publication Number Publication Date
WO2021162532A2 WO2021162532A2 (ko) 2021-08-19
WO2021162532A3 true WO2021162532A3 (ko) 2021-09-30

Family

ID=77292774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/001928 WO2021162532A2 (ko) 2020-02-14 2021-02-15 Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물

Country Status (10)

Country Link
US (1) US20230096928A1 (ko)
EP (1) EP4104820A4 (ko)
JP (1) JP2023513751A (ko)
KR (2) KR102375262B1 (ko)
CN (1) CN115484935A (ko)
AU (1) AU2021219556A1 (ko)
BR (1) BR112022016100A2 (ko)
CA (1) CA3167978A1 (ko)
MX (1) MX2022010044A (ko)
WO (1) WO2021162532A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102583029B1 (ko) * 2020-05-28 2023-09-26 주식회사 아울바이오 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법
US11865213B2 (en) 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
AU2022382676A1 (en) * 2021-11-05 2024-05-23 G2Gbio, Inc. Pharmaceutical kit for parenteral co-administration
WO2024010379A1 (ko) * 2022-07-05 2024-01-11 주식회사 지투지바이오 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법
WO2024077409A1 (en) * 2022-10-09 2024-04-18 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2024128882A1 (ko) * 2022-12-16 2024-06-20 주식회사 펩트론 Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140004198A1 (en) * 2011-01-19 2014-01-02 Novo Nordisk A/S Glp-1 particles and compositions
JP2016515612A (ja) * 2013-04-03 2016-05-30 ドン クック ファーマシューティカル カンパニー リミテッド ドネペジルを含む非経口投与用の医薬組成物
WO2017186075A1 (zh) * 2016-04-26 2017-11-02 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
BR112012028136A2 (pt) * 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
CN102940609B (zh) * 2012-12-12 2018-04-06 上海苏豪逸明制药有限公司 一种高包封率奥曲肽缓释微球及其制备方法
CN105126082B (zh) * 2015-09-22 2022-03-04 齐鲁制药有限公司 一种多肽药物制剂及其制备方法
CN106924750B (zh) * 2015-12-31 2021-03-23 深圳翰宇药业股份有限公司 一种索马鲁肽口服微粒制剂及其制备方法
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
CN107929718A (zh) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
CN110101846B (zh) * 2018-02-01 2022-09-23 齐鲁制药有限公司 一种低突释率的索玛鲁肽微球及其制备方法
CN110623944B (zh) * 2018-06-20 2022-02-08 鲁南制药集团股份有限公司 一种胰高血糖素样肽-1类似物缓释微球制剂及其制备方法
KR102137786B1 (ko) * 2018-07-19 2020-07-24 주식회사 아울바이오 주사제용 미립구의 제조방법
US20210162013A1 (en) * 2018-08-03 2021-06-03 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
KR102186704B1 (ko) * 2019-02-18 2020-12-04 (주)아이엠디팜 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물
EP4005587A4 (en) * 2019-07-29 2023-08-09 Peptron, Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA OR SUPPRESSION OF THEIR PROGRESSION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140004198A1 (en) * 2011-01-19 2014-01-02 Novo Nordisk A/S Glp-1 particles and compositions
JP2016515612A (ja) * 2013-04-03 2016-05-30 ドン クック ファーマシューティカル カンパニー リミテッド ドネペジルを含む非経口投与用の医薬組成物
WO2017186075A1 (zh) * 2016-04-26 2017-11-02 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZOLNIK, B.S., BURGESS, D.J.: "Effect of acidic pH on PLGA microsphere degradation and release", JOURNAL OF CONTROLLED RELEASE, vol. 122, no. 8, 18 September 2007 (2007-09-18), pages 338 - 334, XP022336566, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2007.05.034 *

Also Published As

Publication number Publication date
AU2021219556A1 (en) 2022-09-22
WO2021162532A2 (ko) 2021-08-19
EP4104820A4 (en) 2024-04-17
MX2022010044A (es) 2023-02-22
CN115484935A (zh) 2022-12-16
EP4104820A2 (en) 2022-12-21
KR102375262B1 (ko) 2022-03-16
KR102375262B9 (ko) 2023-04-12
BR112022016100A2 (pt) 2022-10-04
CA3167978A1 (en) 2021-08-19
JP2023513751A (ja) 2023-04-03
KR20220035361A (ko) 2022-03-22
KR20210103985A (ko) 2021-08-24
US20230096928A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
WO2021162532A3 (ko) Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
JP6491174B2 (ja) ニタゾキサニドの制御放出医薬配合物
ES2660544T3 (es) Liberación pulsátil de fármaco
ES2659815T3 (es) Administración inmediata/retardada de fármacos
TWI314868B (en) Pharmaceutical preparation containining 5-methyl-1-phenyl-2-(1h)-pyridone as an active ingredient
JP2020058871A5 (ko)
JP2017222705A5 (ko)
JP2020508338A5 (ko)
JP2019517542A5 (ko)
IL183236A0 (en) Rasagiline orally disintegrating compositions
JP2013018786A (ja) レベチラセタムを含む薬剤組成物及びその調製方法
HRP20231613T1 (hr) Pripravci koji sadrže sredstvo za unošenje i njihova priprava
EP3041511B1 (en) Compositions of eltrombopag
JP2018502898A5 (ko)
JP2020522560A5 (ko)
JP2020514415A5 (ko)
JP2016528171A5 (ko)
US20170231969A1 (en) Pharmaceutical Compositions of Edoxaban
JP2020536121A5 (ko)
CN110753540A (zh) 瑞格列净的口服药物制剂
JP2020512292A5 (ko)
CN113557016A (zh) 衣壳组装调节剂固体配制品
JP5699339B2 (ja) 徐放性製剤
IL307997A (en) Pharmaceutical preparations and intravitreal drug delivery systems for the treatment of eye diseases
WO2020207344A1 (zh) 匹莫齐特和甲氨蝶呤的药物组合及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21754621

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2022548939

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3167978

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022016100

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021754621

Country of ref document: EP

Effective date: 20220914

ENP Entry into the national phase

Ref document number: 2021219556

Country of ref document: AU

Date of ref document: 20210215

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022016100

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220812